Biogenea advances its quantum-classical neoantigen platform with two early-phase trials in colorectal and endometrial cancers, while Elicio and Transgene report positive clinical signals in ongoing trials.
On the methodological front, new AI models address TCR specificity prediction and noncanonical neoantigen discovery, expanding the actionable target space for personalized vaccines.
The Jaime Leandro Foundation for Therapeutic Cancer Vaccines has launched an expanded access protocol for synthetic long peptide neoantigen vaccines in solid tumors. This intermediate patient access initiative highlights growing demand for personalized therapies outside of traditional clinical trial structures.
Washington University School of Medicine is recruiting for a Phase 1 trial evaluating synthetic long peptide personalized cancer vaccines in solid tumors with molecular residual disease. The study tests the hypothesis that these vaccines, co-administered with poly-ICLC, can generate neoantigen-specific T-cell responses sufficient to clear circulating tumor DNA.
Biogenea Pharmaceuticals is initiating an early Phase I study of COLONYVAQ-CRC, a physics-aware, quantum-classical AI-guided personalized neoantigen vaccine for stage III MSS colorectal cancer. The trial combines the vaccine with standard chemotherapy and nivolumab, starting with a 12-patient safety cohort before potentially expanding to 50 patients.
Biogenea is enrolling patients in a Phase I trial for GYNORYLAQ-VLINIVAL, a quantum-classical engine-generated personalized neoantigen vaccine for high-risk endometrial cancer. The study evaluates the safety and feasibility of manufacturing GMP-grade vaccines in a real-world therapeutic context, with secondary objectives focusing on T-cell immunity characterization.
A Phase I trial of a neoantigen vaccine reported a 100% disease-free survival rate in head and neck squamous cell carcinoma (HNSCC). This outcome underscores the potential for personalized vaccines to achieve durable remission in specific solid tumor indications.
Investigational neoantigen vaccines targeting renal cell carcinoma (RCC) mutations have been shown to drive durable T-cell activity. This data supports the biological plausibility of targeting somatic mutations in RCC for therapeutic vaccine development.
A study in Nature demonstrates that a neoantigen vaccine generates antitumour immunity in renal cell carcinoma. This peer-reviewed evidence reinforces the mechanistic basis for vaccine-induced immune responses in RCC patients.
Harvard School of Engineering and Applied Sciences reports that a clinical trial of a personalized cancer vaccine demonstrated feasibility, safety, and immune activation. These results validate the clinical translatability of engineered vaccine approaches in generating measurable immune responses.
Elicio Therapeutics reported antigen spreading to patient-specific neoantigens beyond mKRAS in its Phase 2 AMPLIFY-7P trial. This finding suggests that the vaccine can induce broad immune responses across multiple neoantigens, potentially enhancing efficacy in ongoing Phase 2 development.
Transgene reported positive randomized Phase I data for its individualized neoantigen therapeutic cancer vaccine, TG4050. The company plans to complete randomization for the Phase II part of the trial in Q4 2025, marking a key milestone in the program's clinical progression.
National Cancer Institute reports that neoantigen vaccines are keeping kidney and pancreatic cancers at bay. These findings contribute to the growing body of evidence supporting the clinical utility of personalized neoantigen vaccines across multiple solid tumor types.
Science Partner Journals highlights how artificial intelligence enables the identification of noncanonical neoantigens from the dark genome. This methodological advance expands the pool of potential targets for personalized cancer vaccines beyond traditional coding regions.
Researchers introduced HERMES, a structure-based, physics-guided machine learning model that predicts TCR interactions with peptides on MHC class I alleles. Trained on the protein universe without direct TCR-pMHC data, HERMES achieved up to 0.72 correlation with experimental data and enables de novo design of immunogenic peptides.
A new attention-aware contrastive learning model, ATMTCR, improves the prediction of TCR-antigen binding specificity. By using Transformer encoders and masked contrastive views on large-scale TCR CDR3 sequences, the model extracts high-order semantic information to outperform existing algorithms in predicting neoantigen reactivity.
Analysis of the NASIR-HCC trial shows that neoantigen-specific immune responses can be detected in hepatocellular carcinoma patients, including those who did not benefit from radioimmunotherapy and nivolumab. In vivo experiments in HLA transgenic mice confirmed responses to predicted neoantigens, suggesting potential for vaccine-based strategies in non-responders.